Reuters logo
BRIEF-Immunomedics says antitumor effect of IMMU-132 enhanced with DNA-repair inhibitors
January 9, 2017 / 5:21 PM / a year ago

BRIEF-Immunomedics says antitumor effect of IMMU-132 enhanced with DNA-repair inhibitors

Jan 9 (Reuters) - Immunomedics Inc :

* Immunomedics announces antitumor effect of sacituzumab govitecan (IMMU-132) in triple-negative breast cancer can be enhanced with DNA-repair inhibitors

* Given results obtained thus far with IMMU-132, next step is to combine therapy with PARPI Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below